Economic evaluation of DNA ploidy analysis vs liquid-based cytology for cervical screening
- PMID: 25919612
- PMCID: PMC4580387
- DOI: 10.1038/bjc.2015.95
Economic evaluation of DNA ploidy analysis vs liquid-based cytology for cervical screening
Abstract
Background: DNA ploidy analysis involves automated quantification of chromosomal aneuploidy, a potential marker of progression toward cervical carcinoma. We evaluated the cost-effectiveness of this method for cervical screening, comparing five ploidy strategies (using different numbers of aneuploid cells as cut points) with liquid-based Papanicolaou smear and no screening.
Methods: A state-transition Markov model simulated the natural history of HPV infection and possible progression into cervical neoplasia in a cohort of 12-year-old females. The analysis evaluated cost in 2012 US$ and effectiveness in quality-adjusted life-years (QALYs) from a health-system perspective throughout a lifetime horizon in the US setting. We calculated incremental cost-effectiveness ratios (ICERs) to determine the best strategy. The robustness of optimal choices was examined in deterministic and probabilistic sensitivity analyses.
Results: In the base-case analysis, the ploidy 4 cell strategy was cost-effective, yielding an increase of 0.032 QALY and an ICER of $18 264/QALY compared to no screening. For most scenarios in the deterministic sensitivity analysis, the ploidy 4 cell strategy was the only cost-effective strategy. Cost-effectiveness acceptability curves showed that this strategy was more likely to be cost-effective than the Papanicolaou smear.
Conclusion: Compared to the liquid-based Papanicolaou smear, screening with a DNA ploidy strategy appeared less costly and comparably effective.
Figures



Similar articles
-
The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women.Ann Intern Med. 1999 Jan 19;130(2):97-107. doi: 10.7326/0003-4819-130-2-199901190-00003. Ann Intern Med. 1999. PMID: 10068381
-
Modeling cost-effectiveness of cervical cancer screening in Hungary.Value Health. 2012 Jan;15(1):39-45. doi: 10.1016/j.jval.2011.10.003. Value Health. 2012. PMID: 22264970
-
Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening.Obstet Gynecol. 2006 May;107(5):997-1005. doi: 10.1097/01.AOG.0000210529.70226.0a. Obstet Gynecol. 2006. PMID: 16648402
-
Cost effectiveness of prostacyclins in pulmonary arterial hypertension.Appl Health Econ Health Policy. 2012 May 1;10(3):175-88. doi: 10.2165/11630780-000000000-00000. Appl Health Econ Health Policy. 2012. PMID: 22452448 Review.
-
Cost-effectiveness of cervical cancer prevention.Clin Obstet Gynecol. 2013 Mar;56(1):55-64. doi: 10.1097/GRF.0b013e3182823797. Clin Obstet Gynecol. 2013. PMID: 23318570 Review.
Cited by
-
The Value of DNA Quantitative Cytology Test for the Screening of Endometrial Cancer.Cancer Manag Res. 2019 Dec 11;11:10383-10391. doi: 10.2147/CMAR.S225672. eCollection 2019. Cancer Manag Res. 2019. PMID: 31849527 Free PMC article.
-
Value of automatic DNA image cytometry for diagnosing lung cancer.Oncol Lett. 2018 Jul;16(1):915-923. doi: 10.3892/ol.2018.8723. Epub 2018 May 16. Oncol Lett. 2018. PMID: 29963164 Free PMC article.
-
Overtreatment and Cost-Effectiveness of the See-and-Treat Strategy for Managing Cervical Precancer.Cancer Epidemiol Biomarkers Prev. 2016 May;25(5):807-14. doi: 10.1158/1055-9965.EPI-15-1044. Epub 2016 Feb 29. Cancer Epidemiol Biomarkers Prev. 2016. PMID: 26929242 Free PMC article.
-
The Application of Liquid-Based Cytological Detection for P16, Cytologic Evaluation and High-Risk Human Papillomavirus Testing in Cervical Cancer Screening: A Clinical Evaluation.Int J Womens Health. 2022 Jul 28;14:965-973. doi: 10.2147/IJWH.S365236. eCollection 2022. Int J Womens Health. 2022. PMID: 35924097 Free PMC article.
-
Simple but not simpler: a systematic review of Markov models for economic evaluation of cervical cancer screening.Clinics (Sao Paulo). 2018 Jul 10;73:e385. doi: 10.6061/clinics/2018/e385. Clinics (Sao Paulo). 2018. PMID: 29995100 Free PMC article.
References
-
- Agency for Healthcare Research and Quality 2012. Screening for Cervical Cancer: Clinical Summary of U.S. Preventive Services Task Force Recommendation. AHRQ Publication No. 11-05156-EF-3, March 2012.
-
- Arbyn M, Castellsague X, de Sanjose S, Bruni L, Saraiya M, Bray F, Ferlay J. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22 (12:2675–2686. - PubMed
-
- Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Int J Technol Assess Health Care. 2008;24 (1:10–19. - PubMed
-
- Bocking A, Nguyen VQ. Diagnostic and prognostic use of DNA image cytometry in cervical squamous intraepithelial lesions and invasive carcinoma. Cancer. 2004;102 (1:41–54. - PubMed
-
- Cantor SB, Cardenas-Turanzas M, Cox DD, Atkinson EN, Nogueras-Gonzalez GM, Beck JR, Follen M, Benedet JL. Accuracy of colposcopy in the diagnostic setting compared with the screening setting. Obstet Gynecol. 2008;111 (1:7–14. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources